סיטרבין להזרקה 1 גרם USP

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

CYTARABINE 1 G/VIAL

Disponible depuis:

GENMEDIX

Code ATC:

L01BC01

forme pharmaceutique:

POWDER FOR SOLUTION FOR INJECTION

Mode d'administration:

I.V, S.C, INTRATRACHEAL

Fabriqué par:

BEN VENUE LABORATORIES INC,USA

Groupe thérapeutique:

CYTARABINE

indications thérapeutiques:

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphcytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia.

Date de l'autorisation:

2008-12-01